The additional impact of the hypoxic tumor microenvironment on the expression of molecular targets of oncologic therapies, e.g., the EGFR and its downstream signaling cascades or PD-L1 illustrates the urgent need to investigate such complex interactions to improve the therapeutic response in HNSCC. The gene discussed is EGFR; the disease is neoplasm.